Art. -Nr.: HY-129039

Butyrolactone 3

(Synonyms: MB-3)

13 Cited Publications

Kundenbewertung

Based on 13 publication(s) in Google Scholar

Butyrolactone 3 (MB-3) is a specifical small-molecule inhibitor of the histone acetyltransferase Gcn5 (IC₅₀=100 μM), which has a high affinity to the Gcn5 enzyme comparable to that of its natural substrate, histone H3. Butyrolactone 3 shows weak inhibitory on CBP (IC₅₀=0.5 mM). Butyrolactone 3 can be used in studies of cancer, metabolic, autoimmune and neurological diseases.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.58%
CAS. Nr.: 778649-18-6
Formel: C₉H₁₂O₄
Molecular Weight:184.19

Speicherung:

Powder -20°C, 3 years

* The compound is unstable in solutions, freshly prepared is recommended.

Butyrolactone 3 Chemical Structure

CAS. Nr.: 778649-18-6

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
Chemical Information
Publications (13)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[1]

GCN5

100 μM (IC₅₀)

Alle Histone Acetyltransferase Isoform-spezifische Produkte anzeigen :

In Vitro

Butyrolactone 3 (50, 100, 200 μM, 16 h) can reduce acetylation of Gcn5 and induce degradation of E2A-PBX1^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[3]

Cell Line:

RCH-ACV
Concentration:

50, 100, 200 μM
Incubation Time:

16 h
Result:

Decreased the protein levels of E2A-PBX1 and E2A in a dose-dependent manner.
Reduced Wnt16 and GCN5 protein levels.

Chemical Information

CAS. Nr. 778649-18-6
Appearance Solid
Molecular Weight 184.19
Formel C₉H₁₂O₄
Color White to off-white
SMILES

O=C([C@@H](C1=C)[C@@H](CCC)OC1=O)O
Synonyms

MB-3
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years

* The compound is unstable in solutions, freshly prepared is recommended.

Publications (13)

All Bio/Physico-chemical AssayIPHistological Imaging/StainingIF

Sort by:

Journal Impact Factor

Cancer Discov

Activation of T cell-intrinsic p53 by acetylation elicits antitumor immunity to boost cancer immunotherapy. [Abstract]

2025 Sep 19. PMID: 40970761
Nat Genet

MYC activity at enhancers drives prognostic transcriptional programs through an epigenetic switch. [Abstract]

2024 Apr;56(4):663-674. PMID: 38454021
Mol Cell

Lactylation of XLF promotes non-homologous end-joining repair and chemoresistance in cancer. [Abstract]

2025 Jul 17;85(14):2654-2672.e7. PMID: 40680721
Adv Sci (Weinh)

Lactylated Apolipoprotein C-II Induces Immunotherapy Resistance by Promoting Extracellular Lipolysis. [Abstract]

2024 Oct;11(38):e2406333. PMID: 38981044

Butyrolactone 3 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2024 Oct;11(38):e2406333. [Abstract]

H1299 cells were treated with Lactate (20 mM), A-485, KAT8-IN-1 (300 µM), NU9056 (2 µM), Butyrolactone 3 (MB-3, 300 µM), or Gln-AMS (10 µM) for 14 h. Quantitative analysis of extracellular FFAs was conducted post-treatment.
Pharmacol Res

Histone lysine crotonylation accelerates ACSL4-mediated ferroptosis of keratinocytes via modulating autophagy in diabetic wound healing. [Abstract]

2025 Mar:213:107632. PMID: 39892437
Cell Death Dis

GCN5-mediated regulation of pathological cardiac hypertrophy via activation of the TAK1-JNK/p38 signaling pathway. [Abstract]

2022 Apr 30;13(4):421. PMID: 35490166

Butyrolactone 3 purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2022 Apr 30;13(4):421. [Abstract]

Effects of GCN5 inhibitor Butyrolactone 3 on binding of TAK1 with TAB1 and TAB2 in NRCMs under PE treatment.
J Agric Food Chem

Antimicrobial Peptide BCp12 Inhibits Staphylococcus aureus Growth by Altering Lysine Malonylation Levels in the Arginine Synthesis Pathway. [Abstract]

2022 Jan 12;70(1):403-414. PMID: 34942069
Liver Int

Inhibition of ACSS2 attenuates alcoholic liver steatosis via epigenetically regulating de novo lipogenesis. [Abstract]

2023 Aug;43(8):1729-1740. PMID: 37183518
Int Immunopharmacol

α-Methylene-γ-butyrolactone 3 inhibits the activation of NLRP3 inflammasome in sepsis by blocking both the priming and inflammasome assembly. [Abstract]

2026 Mar 15:173:116305. PMID: 41628514
iScience

Epigenome regulators imbue a single eukaryotic promoter with diverse gene expression dynamics. [Abstract]

2026 Apr 16;29(5):115805. PMID: 42111206
Immunotargets Ther

Inhibitors of KAT2A Alleviate the Progression of AKI by Alleviating Macrophage Ferritinophagy. [Abstract]

2025 Dec 28:14:1515-1529. PMID: 41476772

Butyrolactone 3 purchased from MedChemExpress. Usage Cited in: Immunotargets Ther. 2025 Dec 28:14:1515-1529. [Abstract]

HE staining image of r renal tissues in sham-treated and I/R-treated C57BL/6 mice in the presence or absence of Butyrolactone 3 (10 mg/kg, iv).

Butyrolactone 3 purchased from MedChemExpress. Usage Cited in: Immunotargets Ther. 2025 Dec 28:14:1515-1529. [Abstract]

PAS staining image of kidney from sham-treated and I/R-treated C57BL/6 mice in the presence or absence of Butyrolactone 3 (10 mg/kg, iv).

Butyrolactone 3 purchased from MedChemExpress. Usage Cited in: Immunotargets Ther. 2025 Dec 28:14:1515-1529. [Abstract]

Masson’s trichrome staining in the renal cortex from sham-treated and I/R-treated C57BL/6 mice in the presence or absence of Butyrolactone 3 (10 mg/kg, iv)

Butyrolactone 3 purchased from MedChemExpress. Usage Cited in: Immunotargets Ther. 2025 Dec 28:14:1515-1529. [Abstract]

The expression of KAT2A and F4/80 proteins in kidney tissue of IR-AKI mice was up-regulated by uIRI treatment, and significantly decreased after Butyrolactone 3 (10 mg/kg, iv) treatment.
Neurosci Lett

GCN5/KAT2A contributes to axon growth and neurogenesis. [Abstract]

2022 Jul 27:784:136742. PMID: 35716963
bioRxiv

2026 Jun 22.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (542.92 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

5.4292 mL

27.1459 mL

54.2918 mL

5 mM

1.0858 mL

5.4292 mL

10.8584 mL

10 mM

0.5429 mL

2.7146 mL

5.4292 mL

Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (11.29 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (11.29 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (11.29 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (275 KB)
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Biel M,et al. Design, synthesis, and biological evaluation of a small-molecule inhibitor of the histone acetyltransferase Gcn5.Angew Chem Int Ed Engl. 2004 Jul 26;43(30):3974-6 [Content Brief]

[2]. Haque ME, et al. The GCN5: its biological functions and therapeutic potentials. Clin Sci (Lond). 2021 Jan 15;135(1):231-257. [Content Brief]

[3]. Holmlund T, et al. GCN5 acetylates and regulates the stability of the oncoprotein E2A-PBX1 in acute lymphoblastic leukemia. Leukemia. 2013 Mar;27(3):578-85. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	5.4292 mL	27.1459 mL	54.2918 mL	135.7294 mL
	5 mM	1.0858 mL	5.4292 mL	10.8584 mL	27.1459 mL
	10 mM	0.5429 mL	2.7146 mL	5.4292 mL	13.5729 mL
	15 mM	0.3619 mL	1.8097 mL	3.6195 mL	9.0486 mL
	20 mM	0.2715 mL	1.3573 mL	2.7146 mL	6.7865 mL
	25 mM	0.2172 mL	1.0858 mL	2.1717 mL	5.4292 mL
	30 mM	0.1810 mL	0.9049 mL	1.8097 mL	4.5243 mL
	40 mM	0.1357 mL	0.6786 mL	1.3573 mL	3.3932 mL
	50 mM	0.1086 mL	0.5429 mL	1.0858 mL	2.7146 mL
	60 mM	0.0905 mL	0.4524 mL	0.9049 mL	2.2622 mL
	80 mM	0.0679 mL	0.3393 mL	0.6786 mL	1.6966 mL
	100 mM	0.0543 mL	0.2715 mL	0.5429 mL	1.3573 mL

Keywords

Butyrolactone 3

13 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Butyrolactone 3

MCE Bioactive Compound Library

3D Diverse Fragment Library

Publications Citing Use of MedChemExpress (MCE) Butyrolactone 3

Alle Histone Acetyltransferase Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (13)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Butyrolactone 3

MCE Bioactive Compound Library

3D Diverse Fragment Library

Publications Citing Use of MedChemExpress (MCE) Butyrolactone 3

Alle Histone Acetyltransferase Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (13)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Butyrolactone 3 Related Classifications

HY-129039 Related Classifications